1. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant. 2004; 4:438–443. PMID:
14961999.
2. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369:1215–1226. PMID:
24066742.
3. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012; 12:1157–1167. PMID:
22429309.
4. Opelz G. Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet. 2005; 365:1570–1576. PMID:
15866311.
5. Tait BD, Susal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013; 95:19–47. PMID:
23238534.
6. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005; 352:558–569. PMID:
15703421.
7. Reinsmoen NL, Lai CH, Heidecke H, Haas M, Cao K, Ong G, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation. 2010; 90:1473–1477. PMID:
21030904.
8. Luo L, Lu J, Wei L, Long D, Guo JY, Shan J, et al. The role of HIF-1 in up-regulating MICA expression on human renal proximal tubular epithelial cells during hypoxia/reoxygenation. BMC Cell Biol. 2010; 11:91. PMID:
21092233.
9. Giral M, Foucher Y, Dufay A, Van Huyen JP, Renaudin K, Moreau A, et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant. 2013; 13:2567–2576. PMID:
23919486.
10. Sanchez-Zapardiel E, Castro-Panete MJ, Mancebo E, Morales P, Laguna-Goya R, Morales JM, et al. Early renal graft function deterioration in recipients with preformed anti-MICA antibodies: partial contribution of complement-dependent cytotoxicity. Nephrol Dial Transplant. 2016; 31:150–160. PMID:
26323481.
11. Taniguchi M, Rebellato LM, Cai J, Hopfield J, Briley KP, Haisch CE, et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant. 2013; 13:2577–2589. PMID:
23941128.
12. Lee J, Park Y, Kim BS, Lee JG, Kim HJ, Kim YS, et al. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation. Transplant Proc. 2015; 47:649–652. PMID:
25891704.
13. Zou Y, Stastny P, Susal C, Dohler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med. 2007; 357:1293–1300. PMID:
17898098.
14. Philogene MC, Bagnasco S, Kraus ES, Montgomery RA, Dragun D, Leffell MS, et al. Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies. Transplantation. 2017; 101:608–615. PMID:
27222934.
15. Chung BH, Choi BS, Oh EJ, Park CW, Kim JI, Moon IS, et al. Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy. Transpl Int. 2014; 27:49–59. PMID:
24118413.
16. Fuss A, Hope CM, Deayton S, Bennett GD, Holdsworth R, Carroll RP, et al. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies. Nephrology (Carlton). 2015; 20:467–473. PMID:
25726938.
17. Chung BH, Lee JY, Kang SH, Sun IO, Choi SR, Park HS, et al. Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation. Ren Fail. 2011; 33:150–158. PMID:
21332336.
18. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014; 14:272–283. PMID:
24472190.
19. Banasik M, Boratynska M, Koscielska-Kasprzak K, Kaminska D, Bartoszek D, Zabinska M, et al. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Transpl Int. 2014; 27:1029–1038. PMID:
24909812.
20. Lee J, Huh KH, Park Y, Park BG, Yang J, Jeong JC, et al. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. Nephrol Dial Transplant. 2017; 32:1244–1250. PMID:
26546592.
21. Sanchez-Zapardiel E, Castro-Panete MJ, Castillo-Rama M, Morales P, Lora-Pablos D, Valero-Hervas D, et al. Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period. Transplantation. 2013; 96:70–78. PMID:
23624543.
22. Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM, Acevedo-Calado MJ, Cabello-Chaves V, Gentil-Govantes MA, et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant. 2012; 27:1231–1238. PMID:
21810767.
23. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010; 21:1398–1406. PMID:
20634297.
24. Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, el-Dahr SS. Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol. 1997; 273:F170–F177. PMID:
9249605.
25. Kill A, Tabeling C, Undeutsch R, Kuhl AA, Gunther J, Radic M, et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther. 2014; 16:R29. PMID:
24472528.
26. Win TS, Pettigrew GJ. Humoral autoimmunity and transplant vasculopathy: when allo is not enough. Transplantation. 2010; 90:113–120. PMID:
20531074.
27. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol. 2012; 8:670–678. PMID:
23026942.
28. Cuevas E, Arreola-Guerra JM, Hernandez-Mendez EA, Salcedo I, Castelán N, Uribe-Uribe NO, et al. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies. Nephrol Dial Transplant. 2016; 31:1738–1745. PMID:
27220757.
29. Chung BH, Joo YY, Lee J, Kim HD, Kim JI, Moon IS, et al. Impact of ABO incompatibility on the development of acute antibody-mediated rejection in kidney transplant recipients presensitized to HLA. PLoS One. 2015; 10:e0123638. PMID:
25897756.
30. Kim MG. Does the timing of acute rejection matter with the graft outcome in kidney transplantation? Kidney Res Clin Pract. 2015; 34:123–124. PMID:
26484035.
31. Koo EH, Jang HR, Lee JE, Park JB, Kim SJ, Kim DJ, et al. The impact of early and late acute rejection on graft survival in renal transplantation. Kidney Res Clin Pract. 2015; 34:160–164. PMID:
26484041.
32. Luo L, Li Z, Wu W, Luo G, Xu C, Sun Z, et al. Role of MICA antibodies in solid organ transplantation. Clin Transplant. 2014; 28:152–160. PMID:
24372774.
33. European Renal Best Practice Transplantation Guideline Development G. ERBP guideline on the management and evaluation of the kidney donor and recipient. Nephrol Dial Transplant. 2013; 28(S2):ii1–ii71. PMID:
24026881.
34. Lee H, Kim JI, Moon IS, Chung BH, Yang CW, Kim Y, et al. Investigation of serum angiotensin II type 1 receptor antibodies at the time of renal allograft rejection. Ann Lab Med. 2015; 35:314–320. PMID:
25932439.